Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 136
- Registration Number
- NCT01154829
- Locations
- 🇩🇰
Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup, Glostrup, Denmark
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2015-04-02
- Target Recruit Count
- 252
- Registration Number
- NCT01149655
- Locations
- 🇨🇳
Study Site, Taoyuan County, Taiwan
A Long-Term, Open-Label, Study on Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1210
- Registration Number
- NCT01129674
- Locations
- 🇺🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2020-01-06
- Target Recruit Count
- 709
- Registration Number
- NCT01129882
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
- Conditions
- Interventions
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2021-12-22
- Target Recruit Count
- 173
- Registration Number
- NCT01123707
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
- Conditions
- Interventions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2016-02-08
- Target Recruit Count
- 524
- Registration Number
- NCT01122927
- Locations
- 🇺🇦
Study Site, Vinnytsya, Ukraine
🇺🇦Study Site 2, Kharkiv, Ukraine
🇺🇦Study Site 1, Kharkiv, Ukraine
Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2014-10-03
- Lead Sponsor
- Anne Katrine Pagsberg
- Target Recruit Count
- 300
- Registration Number
- NCT01119014
- Locations
- 🇩🇰
Aalborg Psychiatric Hospital, Aalborg, Denmark
🇩🇰Psychiatric Centre Copenhagen, Rigshospitalet, Copenhagen, Denmark
🇩🇰Hillerød Hospital, Hillerød, Denmark
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
- Conditions
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2021-10-26
- Target Recruit Count
- 237
- Registration Number
- NCT01111552
- Locations
- 🇷🇴
Study Site 1, Bucuresti, Romania
🇷🇴Study Site 2, Bucuresti, Romania
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
- Conditions
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2021-12-21
- Target Recruit Count
- 137
- Registration Number
- NCT01111565
- Locations
- 🇿🇦
Study Site 1, Cape Town, South Africa
🇿🇦Study Site 2, Cape Town, South Africa
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
- Conditions
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2021-10-20
- Target Recruit Count
- 211
- Registration Number
- NCT01111539
- Locations
- 🇮🇳
Study Site 1, Ahmedabad, Gujarat, India
🇮🇳Study Site 2, Ahmedabad, Gujarat, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.